Gerard Edwards, CEO and Director, acquired 600,000 Common Shares on a direct ownership basis at prices ranging from $0.250 to $0.330 between July 6th and 9th, 2018. This represents a $158,000 investment into the company's shares and an account share holdings change of greater than 100%.
In addition, William Gordon Clark Kent, a Senior Officer and Director, acquired 44,000 Common Shares on a direct ownership basis at prices ranging from $0.250 to $0.260 on July 9th, 2018. This represents a $11,140 investment into the company's shares and an account share holdings change of 6.2%.
Meanwhile, Invidx Corp, a 10% Holder, disposed of 37,500 Common Shares between July 6th, 2018 and July 9th, 2018. This represents an account share holdings change of -0.2%.
ChroMedX is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
ChroMedX Corp is a Canada-based medical technology company, which is engaged in the business of research, development and manufacturing of in vitro diagnostics, point of care testing (POCT), blood sample collection, and serum/plasma treatment and analysis. The Company has the following platform technologies: HemoPalm and Automated Ultra Filtration Technology (AUF). HemoPalm focuses on devices and methodologies for blood sample collection and analysis. The initial product in this platform, known as the HemoPalm system, consists of a hand held analyzer and a suite of disposable cartridges for obtaining and testing blood samples. The AUF technology platform is based on ultra filtration and focuses on applying it to several applications.
No Comments